✦ LIBER ✦

A six-month open label assessment of steroid sparing properties of CDP571, a humanized antibody to TNFA in steroid dependent patients with Crohn's disease

✍ Scribed by Feagan, Brian G.; Hanauer, Stephen B.; Cominelli, F.; Sutherland, Lloyd R.; Elson, C.D.; Baker, J.P.; Lichtenstein, G.R.; Archambault, A.; Bernstein, C.; Heath, Patricia K.; Sandborn, William J.

Book ID: 123320948
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 182 KB
Volume: 118
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(00)81227-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A six-month open label evaluation of CDP

A six-month open label evaluation of CDP571, a humanized antibody to TNFa, in active Crohn's disease

✍ Sandborn, William J.; Targan, Stephan R.; Hanauer, Stephen B.; Present, Daniel H 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 181 KB

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human anti body to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease

✍ Feagan, Brian G.; Sandborn, William J.; Baker, J.P.; Cominelli, F.; Sutherland, 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 165 KB

A randomized, placebo-controlled trial o

A randomized, placebo-controlled trial of CDP571, a humanized monoclonal antibody to TNF-α, in patients with moderate to severe Crohn's disease

✍ William J. Sandborn; Brian Feagan; Graham Radford-Smith; Agota Kovacs; Robert En 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 168 KB

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-α, in patients with corticosteroid-dependent Crohn's disease

✍ B. G. Feagan; W. J. Sandborn; J. P. Baker; F. Cominelli; L. R. Sutherland; C. O 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 331 KB